Sugi Predict

Sugi Predict / Compounds / SCHEMBL803901

SCHEMBL803901

SCHEMBL803901

CS(=O)(=O)c1ccc(C#N)cc1

nearest known ligand 0.68

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PTGS2 P35354 1/20 0.68
▸ CA1 P00915 4/20 0.55
▸ CA2 P00918 4/20 0.55
▸ CA9 Q16790 2/20 0.55
▸ CA12 O43570 1/20 0.55
▸ ENPP2 Q13822 2/20 0.50
▸ CYP11B1 P15538 1/20 0.50
▸ CYP11B2 P19099 1/20 0.50
▸ CYP19A1 P11511 1/20 0.48
▸ ALDH1A1 P00352 1/20 0.48
▸ CYP2A6 P11509 1/20 0.48
▸ BCHE P06276 1/20 0.46
▸ ACHE P22303 1/20 0.46
▸ EPHX2 P34913 3/20 0.45
▸ KDM1A O60341 1/20 0.45
▸ CYP2C9 P11712 1/20 0.45
▸ CYP2C19 P33261 1/20 0.45
▸ CYP2J2 P51589 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4190362 0.94 PTGS2 (0.72) PTGS2CA1CA2CA9CA12
SCHEMBL10951291 0.88 PTGS2 (0.57) PTGS2CA1CA2CA9CA12
SCHEMBL5458774 0.88 PTGS2 (0.57) PTGS2CA1CA2CA9CA12
SCHEMBL23882815 0.85 PTGS2 (0.54) PTGS2CA1CA2CA9CA12
SCHEMBL5447738 0.82 PTGS2 (0.51) PTGS2CA1CA2CA9CA12
SCHEMBL8652231 0.82 PTGS2 (1.00) PTGS2
SCHEMBL8974143 0.82 PTGS2 (0.63) PTGS2CA1CA2CA9CA12
SCHEMBL9628592 0.82 CA2 (0.52) PTGS2CA1CA2CA9CA12
SCHEMBL8514633 0.80 CA2 (0.59) PTGS2CA1CA2CA9CA12
SCHEMBL2376239 0.79 ENPP2 (0.72) PTGS2ENPP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 266 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118054087-A Electrolyte, electrolyte injection method and lithium metal battery 蜂巢能源科技股份有限公司 2024-05-17 — — CN claimed
CN-113130994-A Electrolyte and electrochemical device comprising same 深圳市研一新材料有限责任公司 2021-07-16 — — CN claimed
CN-110943253-A High-voltage lithium ion battery combined electrolyte additive, electrolyte and battery thereof 松山湖材料实验室 2020-03-31 — — CN claimed
US-4758312-A Adding colorless electrochemically active compound having positive reduction potential NALCO CHEMICAL COMPANY (US) 1988-07-19 — — US claimed
EP-4200297-B1 IMIDAZO[1,2-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-A]PYRIDINE DERIVATIVES AS TLR9 INHIBITORS FOR THE TREATMENT OF FIBROSIS BRISTOL MYERS SQUIBB CO (US) 2026-05-13 — — EP disclosed
US-12590115-B2 Technologies useful for oligonucleotide preparation WAVE LIFE SCIENCES LTD. (SG) 2026-03-31 — — US disclosed
CN-121726524-A Battery electrolyte and preparation method and application thereof 广州鹏辉能源科技股份有限公司 2026-03-24 — — CN disclosed
US-12552743-B2 Oligonucleotide compositions and methods of use thereof WAVE LIFE SCIENCES LTD. (SG) 2026-02-17 — — US disclosed
US-12486267-B2 Imidazo[1,2-A]pyridine and [1,2,4]triazolo[1,5-A]pyridine derivatives as TLR9 inhibitors for the treatment of fibrosis BRISTOL-MYERS SQUIBB COMPANY (US) 2025-12-02 — — US disclosed
US-20250186425-A1 PPARG INVERSE AGONISTS AND USES THEREOF FLARE THERAPEUTICS INC. 2025-06-12 — — US disclosed
CN-119638644-A Phenothiazine sulfonamide compound or salt thereof, and preparation method and application thereof 郑州大学 2025-03-18 — — CN disclosed
EP-4490147-A1 PPARG INVERSE AGONISTS AND USES THEREOF Flare Therapeutics Inc. (US) 2025-01-15 — — EP disclosed
US-5616601-A 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation GD SEARLE & CO (US) 1997-04-01 — — US disclosed
WO-1996003388-A1 1,2-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1996-02-08 — — WO disclosed
US-4758312-A Adding colorless electrochemically active compound having positive reduction potential NALCO CHEMICAL COMPANY (US) 1988-07-19 — — US disclosed
EP-0237738-A2 Method for in situ corrosion detection using electrochemically active compounds NALCO CHEMICAL COMPANY (US) 1987-09-23 — — EP disclosed
US-4683035-A Method for in situ corrosion detection using electrochemically active compounds NALCO CHEMICAL COMPANY (US) 1987-07-28 — — US disclosed
US-4536599-A HYDROLYZING THE NITRILE DERIVATIVE TO THE AMIDE USING AN ORGANIC QUATERNARY AMINE SALT CATALYST; EFFICIENCY SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1985-08-20 — — US disclosed
EP-0008532-B1 SYNTHESIS OF AMINES SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1983-07-20 — — EP disclosed
EP-0008532-A1 Synthesis of amines SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1980-03-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12552743-B2 Oligonucleotide compositions and methods of use thereof NSUN3, NSUN2, SNRPA1 PTGS2 4030/4885CA1 3879/4885CA2 2884/4885
US-20250186425-A1 PPARG INVERSE AGONISTS AND USES THEREOF PPARG, PPARA, PPARD PTGS2 372/4885CA1 4873/4885CA2 4332/4885
US-12486267-B2 Imidazo[1,2-A]pyridine and [1,2,4]triazolo[1,5-A]pyridine derivatives as TLR9 inhibitors for the treatment of fibrosis TLR9, TLR1, TLR7 PTGS2 1452/4885CA1 4359/4885CA2 1966/4885
US-12590115-B2 Technologies useful for oligonucleotide preparation NOP2, RNGTT, NSUN2 PTGS2 3465/4885CA1 2093/4885CA2 1611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.